{
    "clinical_study": {
        "@rank": "20093", 
        "arm_group": [
            {
                "arm_group_label": "Subjects with hepatic impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Subjects with normal hepatic function", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of\n      oral semaglutide (NNC0113-0217) in subjects with mild, moderate and severe degrees of\n      hepatic impairment compared to subjects with normal hepatic function."
        }, 
        "brief_title": "Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject with normal hepatic function or hepatic impairment (mild, moderate or severe)\n\n          -  Body mass index (BMI) 18.5-40.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of\n             child-bearing potential and not using adequate contraceptive methods\n\n          -  History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease\n\n          -  Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180\n             mmHg and/or diastolic blood pressure above or equal to 100 mmHg)\n\n          -  Any donation of blood or plasma in excess of 400 mL within the 3 months preceding\n             screening\n\n          -  History of significant drug abuse, or a positive drug test at the screening visit\n             (Visit 2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016911", 
            "org_study_id": "NN9924-4082", 
            "secondary_id": [
                "U1111-1139-1272", 
                "2013-000550-21"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Subjects with hepatic impairment", 
                "Subjects with normal hepatic function"
            ], 
            "description": "Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg", 
            "intervention_name": "semaglutide", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bratislava", 
                    "country": "Slovakia", 
                    "zip": "83101"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Slovakia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Poland: Ministry of Health", 
                "Slovakia: State Institute for Drug Control"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the semaglutide plasma concentration curve", 
            "safety_issue": "No", 
            "time_frame": "From time 0 to 24 hours after the 10th dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed semaglutide plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours after the 10th dosing"
            }, 
            {
                "measure": "Area under the SNAC  (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate /salcaprozate sodium) plasma concentration time curve", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to 24 hours after the 10th dosing"
            }, 
            {
                "measure": "Maximum observed SNAC plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours after the 10th dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}